Cardiac Angiosarcoma International Registry

Inclusion Criteria: * Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma. * Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035. * Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations. * Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes. * Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry. * Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis. * Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts. Exclusion Criteria: * Patients who decline to provide informed consent. * Cases where cardiac involvement is secondary to another primary malignancy